Bicara insider plans $396K sale of 17,500 shares
Insider Ryan Cohlhepp filed a Form 144 to potentially sell 17,500 BCAX shares after selling 47,500 shares in the prior three months.
Rhea-AI Filing Summary
Bicara Therapeutics Inc. (BCAX) insider Ryan Cohlhepp filed a Form 144 notice covering a proposed sale of 17,500 shares of common stock through UBS Financial Services Inc., with an estimated aggregate value of $396,200.00, expected on September 8, 2026 on NASDAQ.
The notice also lists prior sales of Bicara common stock by Ryan Cohlhepp over the past three months totaling 47,500 shares for aggregate proceeds of $1,357,661.48.
Positive
- None.
Negative
- None.
Key Figures
Proposed shares to be sold: 17,500 shares
Estimated value of proposed sale: $396,200.00
Shares sold past three months: 47,500 shares
+3 more
6 metrics
Proposed shares to be sold
17,500 shares
Common stock sale planned for September 8, 2026 under Form 144
Estimated value of proposed sale
$396,200.00
Aggregate market value of 17,500 BCAX shares to be sold
Shares sold past three months
47,500 shares
Total BCAX common shares sold by Ryan Cohlhepp in three reported transactions
Aggregate proceeds past three months
$1,357,661.48
Total proceeds from BCAX sales on July 8, 9 and August 10, 2026
July 8, 2026 sale
28,214 shares for $817,584.36
BCAX common stock sold by Ryan Cohlhepp
August 10, 2026 sale
18,750 shares for $524,533.12
BCAX common stock sold by Ryan Cohlhepp
Key Terms
Form 144, Rule 144, attorney-in-fact, Exercise of Stock Option
4 terms
Form 144 regulatory
"144: Filer Information Filer CIK | Filer CCC"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
attorney-in-fact regulatory
"Signature | /s/ UBS Financial Services Inc., as attorney-in-fact for Ryan"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.
Exercise of Stock Option financial
"Common | 09/08/2026 | Exercise of Stock Option | Issuer"
FAQ
What does the latest Form 144 filing disclose for Bicara Therapeutics Inc. (BCAX)?
The filing discloses that insider Ryan Cohlhepp intends to sell up to 17,500 shares of BCAX common stock, with an estimated value of $396,200.00, through UBS Financial Services Inc. on or about September 8, 2026 on NASDAQ.
What prior BCAX stock sales by Ryan Cohlhepp are reported in the last three months?
The notice reports three prior sales: 28,214 shares for $817,584.36 on July 8, 2026; 536 shares for $15,544.00 on July 9, 2026; and 18,750 shares for $524,533.12 on August 10, 2026.
Who is acting on behalf of Ryan Cohlhepp in the Form 144 for BCAX?
The signature block identifies UBS Financial Services Inc. signing as attorney-in-fact for Ryan Cohlhepp, indicating UBS is authorized to act on his behalf for this Form 144 notice regarding Bicara Therapeutics Inc. common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
